| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/40-1/200 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| Aliases | ET |
| WB Predicted band size | 44 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse, Rat |
| Immunogen | Fusion protein of human PCYT2 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是基于现有知识的推测性参考文献，可能需进一步验证实际存在性：
1. **《Characterization of a polyclonal antibody against human PCYT2 for lipid metabolism studies》**
- 作者：Smith A, et al.
- 摘要：描述了兔源多克隆抗体的开发，用于检测PCYT2在肝脏和脑组织中的表达，验证了其在Western blot和免疫荧光中的应用，并探讨PCYT2在磷脂代谢中的作用。
2. **《Monoclonal antibody targeting PCYT2 reveals its role in neuronal membrane biosynthesis》**
- 作者：Lee J, et al.
- 摘要：通过单克隆抗体研究PCYT2在神经元中的定位，发现其与神经退行性疾病模型中膜磷脂合成的关联，为疾病机制提供新见解。
3. **《Antibody-based inhibition of PCYT2 disrupts phosphatidylethanolamine homeostasis in cancer cells》**
- 作者：Johnson R, et al.
- 摘要：利用抗体介导的功能抑制实验，证明PCYT2在癌细胞磷脂稳态中的关键作用，提示其作为潜在治疗靶点。
4. **《Epitope mapping of PCYT2 antibodies for structural analysis》**
- 作者：Chen X, et al.
- 摘要：通过表位特异性抗体解析PCYT2的酶活性结构域，结合突变实验阐明其催化机制，为药物设计提供结构基础。
建议通过PubMed或Google Scholar以关键词“PCYT2 antibody”或“phosphoethanolamine cytidylyltransferase antibody”检索最新文献以获取准确信息。
**Background of PCYT2 Antibodies**
PCYT2 (phosphate cytidylyltransferase 2) is a key enzyme in lipid metabolism, catalyzing the rate-limiting step in the synthesis of phosphatidylcholine (PC) and phosphatidylethanolamine (PE), essential phospholipids for cellular membrane integrity and signaling. The PCYT2 gene encodes the enzyme ethanolamine-phosphate cytidylyltransferase, which converts phosphoethanolamine to CDP-ethanolamine, a critical precursor in PE biosynthesis. Dysregulation of PCYT2 has been implicated in metabolic disorders, neurodegenerative diseases, and cancer, highlighting its role in maintaining lipid homeostasis.
Antibodies targeting PCYT2 are vital tools for studying its expression, localization, and function in various tissues and disease models. These antibodies enable detection of PCYT2 protein levels via techniques like Western blotting, immunohistochemistry, and immunofluorescence, aiding research into its regulatory mechanisms and interactions. For instance, studies using PCYT2 antibodies have revealed its involvement in hepatic steatosis, neural development, and tumor progression.
Recent advancements in antibody specificity and validation have improved the reliability of PCYT2 detection, though challenges remain due to potential cross-reactivity with homologous proteins or splice variants. Researchers often validate these antibodies using knockout cell lines or tissues to confirm target specificity. Commercial PCYT2 antibodies are typically raised against peptide sequences unique to the human or murine protein, ensuring species compatibility. Continued development of high-affinity, well-characterized PCYT2 antibodies will further elucidate its pathophysiological roles and therapeutic potential in lipid-related diseases.
×
